Immunotherapy, a groundbreaking approach in cancer treatment, has transformed the landscape of oncology by empowering the immune system to combat cancer cells more effectively. However, not all cancer patients derive benefits from current immunotherapies, necessitating the identification of predictive biomarkers to determine which patients are most likely to respond positively.
Recent research has shed light on the connection between the ARID1A gene mutation and the response to immune checkpoint blockade, a type of immunotherapy that reactivates cancer-fighting T cells. This mutation is prevalent in various cancers, including endometrial, ovarian, colon, gastric, liver, and pancreatic cancers.
Scientists at the Salk Institute sought to understand how the ARID1A mutation influences treatment sensitivity and how clinicians could leverage this information to customize cancer treatments for individual patients. Their latest study, published in Cell, reveals that ARID1A mutation renders tumors susceptible to immunotherapy by triggering an antiviral-like immune response, inviting cancer-fighting immune cells into the tumor.
The researchers propose that this mutation and antiviral immune response could serve as a biomarker to identify patients who would benefit most from specific immunotherapies, such as immune checkpoint blockade. Furthermore, the findings encourage the development of drugs targeting ARID1A and related proteins to sensitize other tumors to immunotherapy.
Associate Professor Diana Hargreaves, senior author of the study, emphasizes the potential impact on patient outcomes: “These ARID1A mutation cancer patients are already mounting an immune response. Our role is to upregulate that response using immune checkpoint blockade to help them destroy their tumors from within.”
To clarify the relationship between ARID1A mutations and immune checkpoint blockade, Salk researchers investigated mouse models of melanoma and colon cancer with either mutated ARID1A or functional ARID1A. The team observed a robust immune response in all animal models with mutated ARID1A tumors but not those with functional ARID1A tumors, providing evidence that the ARID1A mutation was indeed driving the response. But how does this occur at the molecular level? Stay tuned for further insights.